Protagonist Therapeutics, Inc. Income Statement
PTGX / Health Care|12 years of annual SEC 10-K data (FY2014-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 12 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SG&A Expense | $44.9M | $43.5M | $33.5M | $31.7M | $27.2M | $18.6M | $15.7M | $13.7M | $11.8M | $7.0M | $3.0M | $1.9M |
| R&D Expense | $159.3M | $138.1M | $120.2M | $126.2M | $126.0M | $74.5M | $65.0M | $59.5M | $46.2M | $25.7M | $11.8M | $7.5M |
| Operating Income | -$158.1M | $252.8M | -$93.7M | -$131.4M | -$125.8M | -$64.5M | -$80.5M | -$42.3M | -$37.9M | -$32.7M | -$14.8M | -$9.3M |
| Interest Expense | - | - | - | - | - | $598.0K | $169.0K | - | - | - | - | - |
| Income Tax | $838.0K | $4.2M | $0 | $0 | $0 | $1.3M | -$691.0K | -$799.0K | $0 | $0 | $0 | $0 |
| Net Income | -$130.1M | $275.2M | -$79.0M | -$127.4M | -$125.6M | -$66.2M | -$77.2M | -$38.9M | -$37.0M | -$37.2M | -$14.9M | -$11.1M |
| EPS (Basic) | -$2.05 | $4.47 | -$1.39 | -$2.60 | -$2.71 | -$1.92 | - | - | - | - | - | - |
| EPS (Diluted) | -$2.05 | $4.23 | -$1.39 | -$2.60 | -$2.71 | -$1.92 | - | - | - | - | - | - |
| Shares Outstanding | 63.6M | 65.1M | 56.8M | 49.0M | 46.3M | 34.4M | 25.9M | 22.4M | 17.7M | 6.5M | 251.7K | 227.2K |